Atara Biotherapeutics stock falls on details of secondary stock offering

You are here: Home > Central Coast Health Watch > Current Article

Atara Biotherapeutics stock falls on details of secondary stock offering

By Staff Report / Thursday, January 4th, 2018 / Comments Off on Atara Biotherapeutics stock falls on details of secondary stock offering

Atara Biotherapeutics stock fell 6.5 percent after the company announced details of its proposed secondary stock offering. The Bay Area company expects to raise $127.75 million with the sale of 7 million of its shares at $18.25 each, according to a filing with the Securities and Exchange Commission on Jan. 3. The offering is expected…

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.